[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pathologic-complete-response\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pathologic-complete-response":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100544091","dynamic-multi-omics-integration-model-to-predict-neoadjuvant-therapy-response-in-locally-advanced-rectal-cancer-100544091",false,"NCT06364371","Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer","A Study of the Clinical Value of Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer (T3-4NxM0)","Inclusion Criteria:\n\n1. Histologically confirmed rectal adenocarcinoma;\n2. Clinical stage T3-4NxM0, with or without positive Mesorectum Fascia(MRF), and with or without positive Extra-Mural Venous Invasion(EMVI);\n3. Preoperative staging method: All patients undergo preoperative staging with enhanced CT. Criteria for mesorectal lymph node metastasis: Short axis ≥ 10mm lymph nodes or lymph node morphology and CT characteristics consistent with typical lymph node metastasis. Preoperative chest, abdominal CT, and pelvic MRI exclude distant metastases;\n4. Absence of signs of intestinal obstruction; or relief of obstruction after proximal colon diversion surgery;\n5. No history of previous colorectal surgery;\n6. No history of previous chemotherapy or radiotherapy;\n7. No history of previous biological therapy (such as monoclonal antibodies), immunotherapy \\[such as anti-programmed cell death protein 1(PD-1) antibodies, anti-PD-L1 antibodies, anti-PD-L2 antibodies, or anti-Cytotoxic T Lymphocyte-Associated Antigen-4(CTLA-4)\\], or other investigational drug therapy;\n8. No history of previous hormonal therapy: no restrictions;\n9. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Patients requiring antiarrhythmic therapy (excluding β-blockers or digoxin), symptomatic coronary artery disease, recent myocardial infarction within the past 6 months, or congestive heart failure exceeding New York Heart Association(NYHA) class II;\n2. Poorly controlled severe hypertension;\n3. History of HIV infection or active chronic hepatitis B or C (high viral DNA load);\n4. Active pulmonary tuberculosis (TB) or receiving anti-TB treatment, or having received anti-TB treatment within the past year;\n5. Other active clinically severe infections ;\n6. Evidence of distant metastases outside the pelvis preoperatively;\n7. Cachexia, organ decompensation;\n8. History of pelvic or abdominal radiotherapy;\n9. Multifocal colorectal cancer;\n10. Patients requiring management for epileptic seizures (e.g., with steroids or antiepileptic therapy);\n11. History of other malignant tumors within the past 5 years, excluding cured carcinoma in situ of the cervix or basal cell carcinoma of the skin;\n12. Substance abuse or medical, psychological, or social conditions that may interfere with patient participation in the study or assessment of study results;\n13. Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, hyperthyroidism, hypothyroidism; patients with vitiligo or childhood asthma that has completely resolved and does not require any intervention in adulthood may be included; patients with asthma requiring bronchodilators for medical intervention cannot be included);\n14. Vaccination with any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine, etc.) within 4 weeks before enrollment;\n15. Complications requiring long-term use of immunosuppressive drugs or systemic or local administration of corticosteroids with immunosuppressive effects (dose \\> 10mg\u002Fday of prednisone or equivalent corticosteroids);\n16. Known or suspected allergy to the investigational drug or any medication administered related to this trial;\n17. Any unstable condition or situation that may jeopardize patient safety and compliance;\n18. Pregnancy or lactation in women of childbearing potential who have not taken adequate contraceptive measures;\n19. Refusal to sign the informed consent form.","ALL","18 Years","80 Years",{"count":20,"type":21},106,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to establish a dynamic multi-omics integration model for predicting pathological complete response (pCR) after neoadjuvant treatment in locally advanced (T3-4NxM0) rectal cancer, providing support for subsequent patient selection for the watch-and-wait strategy. The main question it aims to answer is:\n\nWhat is the predictive value of this model to assess individual achievement of pathological complete response (pCR) after neoadjuvant treatment? Eligible patients will be prospectively enrolled, and the clinical features of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative will be collected and annotated.",[25,26],"Predictive Cancer Model","Pathologic Complete Response",[28,29,30,31],"Magnetic resonance imaging","ctDNA","Histopathology slide","CEA","RECRUITING","2025-12-11",{"date":35,"type":36},"2025-12-18","ACTUAL",{"date":38,"type":36},"2024-06-01",{"date":40,"type":21},"2028-06-01",{"name":42,"class":43},"Sixth Affiliated Hospital, Sun Yat-sen University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100574152","application-of-mri-radiomics-features-in-neoadjuvant-therapy-of-head-and-neck-squamous-cell-carcinoma-100574152","NCT06755567","Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n* (a) patients pathologically diagnosed as head and neck squamous cell carcinoma;\n* (b) patients receiving two or three courses of neoadjuvant therapy (traditional chemotherapy plus PD-1 inhibitor);\n* (c) MR scan within 30 days before the first course of neoadjuvant therapy;\n* (d) patients undergoing radical surgical dissection following neoadjuvant therapy;\n* (e) complete clinical data available.\n\nExclusion Criteria:\n\n* (a) previous head and neck treatment history;\n* (b) obvious motion or metal artifacts on the MRI image;\n* (c) distant metastasis;\n* (d) concurrent malignancies.",{"count":52,"type":21},750,"Head and neck squamous cell carcinoma is the sixth most common malignant tumor in the world. Neoadjuvant therapy, including neoadjuvant chemotherapy and immunotherapy, is recommended for patients with locally advanced head and neck cancer. The response to neoadjuvant therapy varies among the patients. It is reported that about 37% of the patients achieve pathological complete response after receiving neoadjuvant therapy, who would achieve a better prognosis compared with the patients with non-pathological complete response. It is significant to predict and assess response to neoadjuvant therapy for the patients with head and neck cancer accurately, which could assist in formulating individualized therapeutic regimens. MRI has good soft tissue resolution and is a common preoperative examination method. However, this method lacks the ability to accurately predict the probability of patients achieving pathological remission after neoadjuvant therapy. At present, it is a novel and effective method to construct a model to predict the efficacy of neoadjuvant therapy based on MRI image omics analysis, and certain achievements have been made in breast cancer and rectal cancer. In this study, multi-sequence MRI was combined with clinical risk factors to construct an imaging omics model to predict the probability of pathological complete remission of patients with head and neck squamous cell carcinoma after neoadjuvant therapy, and to accurately identify diagnostic imaging remission, so as to better assist clinical decision-making.",[55,56,57,58,26],"Head and Neck Cancer","Neoadjuvant Therapy","Immunotherapy","Chemotherapy","NOT_YET_RECRUITING","2024-12-24",{"date":62,"type":36},"2025-01-01",{"date":64,"type":21},"2024-12-25",{"date":66,"type":21},"2028-12-31",{"name":68,"class":43},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":44},"100530121","the-prognostic-value-of-the-degree-of-pathological-response-of-induction-chemotherapy-for-npc-100530121","NCT06182657","The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC","The Prognostic Value of the Degree of Pathological Response at One Cycle of Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinon-a Prospective Observational Study","Inclusion Criteria:\n\n1. Ability to sign informed consent\n2. Age \\> 18 years at time of study entry\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (amend based on specific study)\n4. Histological confirmation of NPC (regardless if EBER positive or negative)\n5. Locally advanced NPC, UICC stage III-IVa\n6. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n\nExclusion Criteria:\n\n1. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\n2. Distant metastases\n3. Prior systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, radiotherapy, biologic therapy, tumour embolization, monoclonal antibodies) of the locally advanced NPC.\n4. History of another primary malignancy\n5. Female patients who are pregnant\n6. Known allergy or hypersensitivity to any drugs\n7. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.",{"count":77,"type":21},300,"This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle induction chemotherapy, including the density of immune cells infiltration and tertiary lymphoid structures.",[80,26,81],"Nasopharyngeal Carcinoma","Tumor Microenvironment","2024-02-07",{"date":84,"type":36},"2024-02-08",{"date":86,"type":36},"2024-01-01",{"date":88,"type":21},"2029-06-30",{"name":90,"class":43},"Jiangxi Provincial Cancer Hospital"]